The Anagen-Extension Hypothesis: How Treatments Lengthen Growth Phases

AGA is fundamentally a disease of shortened anagen. Treatments that extend anagen — by reducing DHT or improving follicle vascularity — reverse the core biology. The clinical effects follow from the mechanism.

Androgenetic alopecia is at its mechanistic core a disease of shortened anagen — the growth phase of the hair cycle. Every hair cycle in an AGA-affected follicle is slightly shorter than the last, resulting in progressively shorter, finer hairs before each telogen shedding event. The most effective treatments for AGA share anagen extension as a core mechanism.

The normal hair cycle and AGA deviation

In a healthy terminal scalp follicle, anagen lasts approximately two to seven years. Each follicle completes approximately three to five cycles before the hair shaft reaches its maximum length (genetically determined). During AGA, each successive cycle shortens anagen — not abruptly, but progressively over years. A follicle that once had four-year anagen may cycle with two-year anagen five years into AGA, and six-month anagen fifteen years in. The visible result: shorter hairs that do not grow long enough to contribute to visible scalp coverage even when still present.

Measuring anagen extension

Clinical evidence for anagen extension comes from phototrichogram studies measuring the anagen:telogen ratio before and after treatment. Finasteride trials show statistically significant increases in the anagen proportion at six months and beyond, with corresponding decreases in telogen proportion. The increased anagen fraction directly reflects extended anagen duration across the follicle population in the treatment zone.

Downstream clinical effects of anagen extension

Longer anagen produces three clinically measurable changes:

• Increased hair shaft length: Hairs that spend more time in anagen grow longer before shedding — contributing more to scalp coverage even before density changes are detectable
• Increased hair shaft diameter: Matrix cells operating through a longer anagen period produce a fuller-calibre fibre before the anagen-terminating signals dominate
• Decreased shed rate: Hairs in anagen are not shed; more follicles in anagen at any given time means fewer entering telogen each month

These three effects together — longer, thicker, and fewer shed hairs — produce the clinical improvement observed with effective AGA treatment, all downstream of the anagen extension mechanism.